Insulin resistance is often associated with obesity and can precipitate type 2 diabetes. To date, most known approaches that improve insulin resistance must be preceded by the amelioration of obesity and hepatosteatosis. Here, we show that this provision is not mandatory; insulin resistance and hyperglycemia are improved by the modification of hepatic fatty acid composition, even in the presence of persistent obesity and hepatosteatosis. Mice deficient for Elovl6, the gene encoding the elongase that catalyzes the conversion of palmitate to stearate, were generated and shown to become obese and develop hepatosteatosis when fed a high-fat diet or mated to leptin-deficient ob/ob mice. However, they showed marked protection from hyperinsulinemia, hyperglycemia and hyperleptinemia. Amelioration of insulin resistance was associated with restoration of hepatic insulin receptor substrate-2 and suppression of hepatic protein kinase C epsilon activity resulting in restoration of Akt phosphorylation. Collectively, these data show that hepatic fatty acid composition is a new determinant for insulin sensitivity that acts independently of cellular energy balance and stress. Inhibition of this elongase could be a new therapeutic approach for ameliorating insulin resistance, diabetes and cardiovascular risks, even in the presence of a continuing state of obesity.

Proper control of hepatic glucose production is central to whole body glucose homeostasis and its disruption plays a major role in diabetes. Here we demonstrate that, although established as an intracellular lipid chaperone, aP2 is in fact actively secreted from adipocytes to regulate liver glucose metabolism. Fasting and lipolysisrelated signals regulate secretion of aP2 from adipocytes, and circulating aP2 levels are markedly elevated in mouse and human obesity. Recombinant aP2 stimulates glucose production and gluconeogenic activity in primary hepatocytes in vitro and in lean mice in vivo. In contrast, neutralization of secreted aP2 reduces glucose production and corrects the diabetic phenotype of obese mice. Hyperinsulinemiceuglycemic and pancreatic clamp studies demonstrated actions of aP2 in liver upon aP2 administration or neutralization. We conclude that aP2 is a novel adipokine linking adipocytes to hepatic glucose production and that neutralizing secreted aP2 may represent an effective therapeutic strategy for diabetes.

Leptin-deficient ob/ob mice show many characteristics of obesity, including excess peripheral adiposity as well as severe hepatic steatosis, at least in part, due to increased hepatic lipogenesis. Polyunsaturated fatty acids (PUFAs) are not only ligands for peroxisome proliferator-activated receptor (PPAR) ␣ but are also negative regulators of hepatic lipogenesis, which is thought to be mediated by the repression of sterol regulatory element-binding protein ( S terol regulatory element-binding proteins (SREBPs) are members of the basic helix-loop-helix leucine zipper family of transcription factors that regulate fatty acid and cholesterol synthesis (reviewed in Brown and Goldstein 1 ). Unlike other members of the family, SREBPs are synthesized as precursors bound to the endoplasmic reticulum and nuclear envelope and are released from the membrane into the nucleus as mature proteins by cleavage processes. To date, 3 isoforms of SREBP, -1a, -1c, and -2, have been identified and characterized. The predominant SREBP-1 isoform in liver and adipose tissue is SREBP-1c. Whereas SREBP-2 plays a crucial role in regulation of cholesterol synthesis, SREBP-1c controls the transcription and expression of lipogenic enzymes such as fatty acid synthase (FAS) and stearoyl-CoA desaturase 1 (SCD1) (reviewed in Shimano 2 and Horton et al. 3 ). It is remarkable that SREBP-1c regulates not only the synthetic rate of triglycerides but also the amount of their storage in the liver. 4,5 Thus, SREBP-1 has been revealed to be a promising target for hepatic steatosis (fatty livers) from a therapeutic point of view.The leptin-deficient ob/ob mouse model of obesity exhibits severe obesity and obesity-related symptoms, including hepatic steatosis and insulin resistance (reviewed in Bray and York 6 ). The livers of ob/ob mice have an increase in triglyceride content, probably because of the increased lipogenesis paralleled by elevated messenger RNA (mRNA) expression and enzymatic activity of several lipogenic enzymes such as FAS and SCD1. 6,7 Recently, it has been reported that both SREBP-1c mRNA and its active nuclear protein are increased in ob/ob mouse livers. 8 Furthermore, we have demonstrated in a previous report 5 that the disruption of the SREBP-1 gene in ob/ob mice leads to marked amelioration of hepatic steatosis.Dietary polyunsaturated fatty acids (PUFAs) of the n-6 and n-3 families are well established as negative regulators of hepatic lipogenesis (reviewed in Clark and Jump 9 ). Recently, others and we have shown that the suppressive

The tumor suppressor p53 is a transcription factor that activates or represses its target genes after various genotoxic stresses. We have previously shown that sterol regulatory element-binding protein-1 (SREBP-1), a key transcriptional regulator of triglyceride synthesis, and the lipogenic enzymes under its control are markedly suppressed in adipocytes from genetically obese ob/ob mice. Here we demonstrate that p53 and its target genes are highly induced in adipocytes of ob/ob mice in a fed state, leading to the negative regulation of SREBP-1 and thereby lipogenic genes. In fact, disruption of p53 in ob/ob mice completely suppressed the p53-regulated genes to wild-type levels and partially restored expression of lipogenic enzymes. Consistently, reporter gene analysis showed that p53 overexpression suppressed the promoter activity of the SREBP-1c gene and its downstream genes. Thus, the activation of p53 might constitute a negative feedback loop against excess fat accumulation in adipocytes. In conclusion, we discovered a novel role of p53 in the pathophysiology of obesity.Obesity is a major health problem in industrialized societies, affecting ϳ20 -40% of adults (1). The genetically obese ob/ob mice develop obesity, insulin resistance, and glucose intolerance owing to an inherited deficiency of the appetite-suppressing hormone, leptin (2-6). The absence of leptin presents the most severe obesity known in both rodents and humans (7), and provides a good model of obesity and its related syndromes, including insulin resistance. Although the underlying mechanisms that link obesity and defective insulin signaling are as yet undefined, hypertrophied adipocyte-derived cytokines such as tumor necrosis factor (TNF) 1 -␣ have been reported to be mediators of insulin resistance in obesity (8,9).In the insulin signaling pathways, a transcription factor sterol regulatory element-binding protein-1 (SREBP-1) has recently been established to be a key molecule for the transcriptional regulation of triglyceride synthesis (10). SREBPs are members of the basic helix-loop-helix leucine zipper family of transcription factors that regulate fatty acid and cholesterol synthesis (reviewed in Refs. 11-13). Whereas SREBP-2 plays a crucial role in regulation of cholesterol synthesis, SREBP-1 controls the transcription and expression of lipogenic enzymes such as fatty acid synthase (FAS) (reviewed in Refs. 14 -17). In fact, SREBP-1 and its downstream lipogenic enzymes are drastically induced when fasted animals are refed (18). These lipogenic genes belong to the group of genes that are induced most strongly by glucose/insulin 2 and can be regarded as indicators of insulin signaling.We have recently reported that the refeeding responses of SREBP-1 and its downstream lipogenic enzymes are markedly suppressed in adipocytes of ob/ob mice, which is presumably associated with impaired insulin signaling (19). Although the precise role of this down-regulation is currently undefined, it could be a negative feedback mechanism to prevent excess fat ac...

Liver X receptors (LXRs) and peroxisome proliferator-activated receptors (PPARs) are members of nuclear receptors that form obligate heterodimers with retinoid X receptors (RXRs). These nuclear receptors play crucial roles in the regulation of fatty acid metabolism: LXRs activate expression of sterol regulatory element-binding protein 1c (SREBP-1c), a dominant lipogenic gene regulator, whereas PPARalpha promotes fatty acid beta-oxidation genes. In the current study, effects of PPARs on the LXR-SREBP-1c pathway were investigated. Luciferase assays in human embryonic kidney 293 cells showed that overexpression of PPARalpha and gamma dose-dependently inhibited SREBP-1c promoter activity induced by LXR. Deletion and mutation studies demonstrated that the two LXR response elements (LXREs) in the SREBP-1c promoter region are responsible for this inhibitory effect of PPARs. Gel shift assays indicated that PPARs reduce binding of LXR/RXR to LXRE. PPARalpha-selective agonist enhanced these inhibitory effects. Supplementation with RXR attenuated these inhibitions by PPARs in luciferase and gel shift assays, implicating receptor interaction among LXR, PPAR, and RXR as a plausible mechanism. Competition of PPARalpha ligand with LXR ligand was observed in LXR/RXR binding to LXRE in gel shift assay, in LXR/RXR formation in nuclear extracts by coimmunoprecipitation, and in gene expression of SREBP-1c by Northern blot analysis of rat primary hepatocytes and mouse liver RNA. These data suggest that PPARalpha activation can suppress LXR-SREBP-1c pathway through reduction of LXR/RXR formation, proposing a novel transcription factor cross-talk between LXR and PPARalpha in hepatic lipid homeostasis.